Is Tivozanib covered by medical insurance?

Tivozanib, trade nameFotivda, is a drug used to treat advanced renal cell carcinoma (kidney cancer). It is an oral VEGF receptor tyrosine kinase inhibitor. The most common side effects include fatigue, high blood pressure, diarrhea, decreased appetite, nausea, dysphonia (change in voice), hypothyroidism, cough, and stomatitis.

Tivozanib was discovered in Kyowa Kirin and developed by Aveo Pharmaceuticals. In the United States, tivozanib is indicated for adult patients with advanced renal cell carcinoma that has relapsed or is refractory after two or more systemic therapies. In the EU, it is indicated for the treatment of adults with advanced renal cell carcinoma; for the first-line treatment of adults with advanced renal cell carcinoma, and for use in adults whose disease has progressed after a prior course of factor therapy in advanced renal cell carcinoma for which inhibitors of the VEGFR and mTOR pathways have not been identified. Tivozanibshould not be mixed with St. John's wort (an inducer of the liver enzyme CYP3A4). Women should not take this product during pregnancy because tivozanib is teratogenic, embryotoxic, and fetotoxic in rats. The prescribing information will advise females of reproductive potential to use effective contraception during treatment with tivozanib and for one month after the last dose. .

The original drug Tivozanib has not yet been marketed in the country, so it has not been included in medical insurance. The European version of tivozanib Original drug, specifications1340mcg*21 pills sold overseas may cost around 30,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic version of tivozanib available on the market. For more drug information and specific prices, please consult a medical consultant.